CG Oncology (CGON) Investor presentation summary

Market opportunity and disease landscape

• Non-muscle invasive bladder cancer (NMIBC) represents about 75% of newly diagnosed bladder cancer cases, creating a multi-billion dollar market opportunity.

• More than 70% of NMIBC market potential is addressed by cretostimogene programs across high- and intermediate-risk populations.

• Annualized wholesale acquisition cost (WAC) of approved therapies in high-risk NMIBC ranges from $200K to $690K, with over 150,000 addressable patients.

Product profile and clinical efficacy

• Cretostimogene is an investigational oncolytic immunotherapy administered intravesically, similar to standard BCG therapy.

• Demonstrated 75.5% overall complete response (CR) in BOND-003 Cohort C, with 46.4% CR at 12 months and 41.8% at 24 months.

• In BOND-003 Cohort P, high-grade event-free survival (HG-EFS) was 95.7% at 3 months, 84.6% at 6 months, and 80.4% at 9 months.

• No grade ≥3 treatment-related adverse events (TRAEs) or deaths reported; most adverse events were grade 1-2.

Competitive positioning and safety

• Cretostimogene shows best-in-disease long-term durability and safety compared to approved drugs, with 41.8% CR at 24 months and 0% grade 3+ TRAEs.

• High initial response rates in BCG-naïve patients (88% CR with optimized instillation in CORE-008 Cohort A).

• Combination studies (e.g., with gemcitabine) show high complete response rates and favorable safety in BCG-exposed/unresponsive populations.